Several fluorescent molecularly imprinted nanogels for the detection of the anticancer drug sunitinib were synthesized and characterised. A selection of functional monomers based on different aminoacids and coumarin allowed isolation of polymers with very good rebinding properties and sensitivities. The direct detection of sunitinib in human plasma was successfully demonstrated by fluorescence quenching of the coumarin-based nanogels. The plasma sample simply diluted in DMSO allowed the recovery of various amounts of sunitib, as determined by an averaged calibration curve. The LOD was 400 nM, with within-run variability < 9%, day to day variability < 5%, and good accuracy in the recovery of sunitinib from spiked samples.
Introduction
Keeping toxicity to a minimal level while ensuring optimal activity and minimal side effects are key priorities in cancer therapy, however, individual germ line mutations, in metabolizing enzymes, and other pharmacogenomics variations may vary pharmacokinetic and pharmacodynamic responses within a pool of individuals. Therapeutic drug monitoring, aimed at obtaining personalized medicines, is one of the main targets in current clinical oncology (Walko and McLeod 2014; De Jonge at al. 2005; Alnaim 2007 ). At present, therapeutic drug monitoring (TDM) heavily relies on drug extraction and quantification from blood or plasma samples by HPLC (Mohammadi et al. 2010) or LC-MS (Marangon et al. 2015; Van Erp et al. 2013 ). The instrumentation required for these analyses is expensive and dependent on highly specialised personnel, therefore limiting the applicability. The development of a point of care
device, that allows tailoring of the therapy protocol upon individual responses, with simple sample preparation, high sensitivity and good selectivity, remains a challenge.
In recent years molecular imprinting has consolidated its place as a viable approach for the generation of polymeric matrices with excellent molecular recognition characteristics. The templating approach, together with an appropriate choice of functional monomer and crosslinker, allows the formation of three-dimensional cavities that can rebind the target molecule, or its analogues, with high selectivity.
In the field of therapeutic drug monitoring, imprinted polymers (MIPs) have been developed for pre-concentration of samples, as purification cartridges for LC-MS analysis (Thibert et al. 2014; Yang et al. 2014) , or as recognition elements for microbalances, plasmon resonance and electrochemical systems (Altintas et al. 2015; Blanco-Lòpez et al. 2004) . Alternatively, MIPs have also been used as the sensing system, by embedding the signal-generating monomer in the polymeric matrix, such as in the case of optical/fluorimetric units (Manju et al. 2010; Awino and Zhao 2014; Ton et al. 2013) . In terms of polymer matrices, most work has been done with bulk polymers, acting as recognition elements for electrochemical, quantum dots or fiber optic based sensors. MIP-based electrochemical sensors have been used to detect uracil- (Prasad et al. 2012; Prasad et al. 2009 ) and anthraquinone-based anticancer drugs (Nezhadali et al. 2016 ).
CdTe@SiO2 quantum dots coated with a MIP were used as fluorescent sensor for norepinephrine , and fiber optic array was developed to quantify enrofloxacin in sheep serum (Carrasco et al. 2015) .
The main target of this work was to develop fluorescent imprinted nanogels, specific for anticancer drugs, that would form stable colloidal solutions when dispersed into human plasma, therefore allowing detection of the target with minimal sample preparation.
Plasma is a very complex matrix, containing thousands of different molecules and binding proteins such as albumins and immunoglobulins. A potential sensor for the quantification of drugs must overcome key issues like the possible cross-reactivity with plasma proteins and small molecules, competitive binding of the drug to albumin, stability issues leading to aggregation and precipitation of the nanoparticles.
For the purpose of this work sunitinib (SU11248, Sutent) 1 (Figure 1 ) was selected as the target drug. Sunitinib is a tyrosine kinase inhibitor used for the treatment of renal cell carcinoma and of imatinib-resistant gastrointestinal stromal tumour since 2006 (Noble et al. 2004; Zhang et al. 2009 ). It is commonly administered to patients as sunitinib malate, with dosages ranging from 25-50 mg to 150 mg daily. Pharmacokinetic and pharmacodynamic preclinical studies demonstrated that although the therapeutic window of concentrations for sunitinib is between 50 ng/mL and 500 ng/mL, concentrations higher than 100 ng/mL result in a significant increase in drug toxicity (Faivre et al. 2006; Kollmannsberger et al. 2011) . Therefore, the TDM of this drug represents a useful system to develop personalized therapies for patients decreasing side effects and increasing therapy efficiency. As for other anticancer drugs, sunitinib quantification in plasma is currently performed by HPLC coupled with UV detector (Etienne-Grimaldi et al.
2009
; Blanchet et al. 2009 ) or mass spectrometer (De Bruijn et al. 2010) or by LC/MS/MS methods (Andriamanana et al. 2013) . Currently there are no rapid methods available for the therapeutic monitoring of sunitinib in alternative to such high specialised equipment, and point of care devices or immunoenzymatic assays for anticancer drugs have yet to be reported.
Materials and Methods

Materials:
Sunitinib was purchased from Bepharm ltd. All the other reagents were from Sigma-Aldrich.
Instrumentation: HPLC analyses were run on an Agilent series 1100 liquid chromatograph equipped with a Phenomenex, Luna C18 5 column with a column guard and a 20 L loop.
The flow was set to 1 mL min -1 . UV-visible spectra were recorded on a UV-1800 (Shimadzu) 53.21, 110.14, 111.41, 118.76, 119.89, 122.41, 122.90, 127.29, 127.82, 130.56, 136.33, 165.13, 172.38 = 110.57, 116.27, 116.86, 118.49, 127.44, 128.70, 133.82, 142.96, 153.23, 154.85, 160.45, 163.90. MS ESI m/z: 238.9 [M+Na] + ; IR:  cm -1 = 1734.
H NMR titrations
Weighted amounts of functional monomer 3b, 4b, 5b were added to a 6.7 mM solution of sunitinib in DMSO-d6 so that the concentration of functional monomer varied from 3.35 mM to 93.7 mM. Sunitinib (6.7 mM) was also titrated with 4-vinylpyridine (2) using a 1.15 M mother solution in DMSO-d6. The 1 H NMR spectrum of the resulting solutions were recorded after every addition. (Figure 1 ).
Synthesis of molecularly imprinted polymers (general procedure)
The functional monomer (1 equiv) and the template drug (1.2 equiv) were stirred in DMSO, in anhydrous conditions, for 40 minutes. The resulting solution was transferred in a crimp cap Wheaton vial and N, 4.7 equiv) , recrystallized 1 AIBN (18% mol, calculated on the amount of the available double bonds, 2.1 equiv) and acrylamide (1equiv) were added. DMSO was adjusted so as to correspond to 99% of total monomers and crosslinker (in weight) and the vial was evacuated, flushed with argon (3 x 10 minutes) and then kept at 70°C for 4 days. Each polymer was synthesised both in presence of the template molecule, leading to MIP particles, and without the template, leading to NIP (non-imprinted polymers). The resulting clear solutions were dialyzed (cut off 3.5 kDa) against methanol for 2 days and against water for other 2 days, changing the solvent 3 times per day. Finally, the solutions were freeze-dried giving a fluffy solid. The composition and quantities of the polymerization mixtures for each nanogels are reported in Table S1 . The solid polymers were reconstituted at the desired concentration by dispersing the nanogels in the required solvent, sonnication for 10 minutes and filtration using Micron filter (0.25m pore size).
Dynamic laser light scattering
Characterisation of particle size was done in the same solvent system that was used for the rebinding assays in plasma. The size distribution by number, intensity and by volume was recorded in triplicate for solutions of all MIPs and NIPs (0.25 mg mL -1 , 10% H2O in DMSO).
Transmission electron microscopy MIP 1.4 (1.08 mg) was dissolved in 2.16 mL of distilled water, the solution was stirred for 10 minutes and sonicated for 15 minutes. The resulting solution was dialyzed for 24 h at 25°C in distilled water using a pre-wetted Float-A-Lyzer ® G2 with MWCO = 3.5 -5.0 kDa (obtained by Spectrumlabs). The solution was then filtered through a 0.45 μm GHP membrane and a 2.0 μl were added to graphene oxide grid (GO support film on Lacey carbon on 400 mesh Cu grid, Agar Scientific) and imaged at TEM.
Rebinding tests of the drug
A mixture of polymer (1.5 mg) and the drug (50 M) in 1.5 mL water was incubated at 25°C
with continuous stirring; 200 L aliquots were taken after 1 h, 3 h, 8 h and spiked with 50 L of a 1 M solution of a reference standard. Each aliquot was centrifuged (10000 rpm for 6 min) and the supernatant, containing an unknown amount of the drug and 25 M reference, was analysed by HPLC to quantify the drug concentration. The reference standard for sunitinib was caffeic acid and the mobile phase was 75 : 25 water : acetonitrile with 0.05% of TFA, wavelength: 265 nm.
Cross reactivity tests with SN38 and paclitaxel were performed in the same manner with 50 µM SN38 or paclitaxel in water, using 25 µM quinolinone as reference. SN38 was analysed with 78 : 22 water : acetonitrile mixture containing 0.05% TFA as the mobile phase, a flux of 1 mL/min and the detector fixed at 208 nm wavelength. For paclitaxel, 55 : 45 water : acetonitrile containing 0.05% TFA was used as the mobile phase with a flux of 1 mL/min, and the wavelength was set at 230 nm.
Fluorimetric characterization of the polymers
The fluorescence of 60 g/mL solutions of the fluorescent polymers in water containing 3% DMSO and sunitinb ranging from 0 to 88.8 M was measured at the following wavelengths:
303 nm (emission) and 274 nm (excitation) for polymers containing tyrosine; 340 nm 
Fluorescence assay in plasma
Calibration curve. A 1.0 mg/mL solution of MIP 1.5 in DMSO was diluted to a final 60 µg/mL concentration in 4 : 1 DMSO : water. In order to obtain the calibration curve, 400 µL of this solution were titrated with increasing amounts of 400 µM and 4 mM sunitinib solutions in 4 :
1 DMSO-water so that the final sunitinib concentration was in the 1 µM -154 µM range.
Spiked samples. The spiked samples at 5 µM, 20 µM, 50 µM and 80 µM sunitinib were made diluting a 4 mM sunitinib solution with 50 mg/mL HSA in PBS or with plasma to the required concentrations. DMSO (400 L) was added to 100 L of this solution and the mixture was centrifuged. MIP was added to the supernatant so that the final polymer concentration was 60 µg/mL and the fluorescence of the solution was measured at the following wavelengths: 456 nm (emission) and 327 nm (excitation) with bandwidths set at 5 nm.
Results and discussion
Functional monomers
The formation of a stable complex between the functional monomer and the template in the prepolymerisation mixture is a key requirement in molecular imprinting for obtaining matrices with high rebinding characteristics. Four functional monomers were selected for their potential ability to interact with Sunitinib, the target drug, via a variety of non-covalent interactions.
Sunitinib (Figure 1 ) contains three hydrogen bond donor NH groups, three hydrogen bond acceptors (two carbonyls and a tertiary amino group), an extended aromatic system capable of π-staking, and four alkyl sites candidates for van der Waals and hydrophobic interactions. 4-Vinyl pyridine 2 is a functional monomer that may interact by π-π stacking and hydrogen bonds to the nitrogen atom and has been chosen as a reference monomer, being commercially available. N-acryloyl-tyrosine methyl ester 3b and N-acryloyl-tryptophan methyl ester 4b were selected to exploit biomimetic recognition of the targets by the amino acid side chains. In addition, tryptophan has the advantage of being fluorescent with an emission at 340 nm (excitation at 280 nm). The static quenching of this fluorescence by many interacting molecules is often exploited in studies of protein-small molecule interactions (Luisi et al. 2013 ). 7-Acryloyloxy-coumarin 5b contains the coumarin fluorophore that emits visible light at 460 nm upon excitation at 330 nm: this feature, and its molecular structure, potentially capable of establishing π-π stacking interactions with the aromatic regions of Sunitinib, may lead to a lightemitting sensor that can be switched off when binding the target.
Compounds 3b, 4b, 5b were obtained by acylation of the corresponding precursors 3a-5a with acryloyl chloride following previously reported procedures (Bentolila et al. 2000; Moore and O'Relly 2012; Sinkel et al. 2010 ).
In order to assess whether compounds 3b-5b can establish strong interactions with the target, a series of 1 H-NMR titrations were performed in DMSO by adding different concentrations of functional monomer to a fixed concentration of sunitinib and monitoring changes in the chemical shifts of protons involved in the interaction (Athikomrattanakul et al. 2009 ). The data reported in Figure 1 confirm that Sunitinib interacts with all four functional monomers; its indole and methylidene groups make hydrophobic contacts with the aromatic system of 7-acryloyloxy-coumarin 5b; the formation of hydrogen bonds between the indole NH proton and acceptors of N-acryloyl-tryptophan methyl ester 4b and 4-vinyl pyridine 2b is also observed; in addition the amide proton of sunitinib is also involved in hydrogen bonding to 4b. The interactions with N-acryloyl-tyrosine methyl ester 2b are weaker and involve mainly the amide group of sunitinib. The strongest interactions are observed with 5b and 4b, which appear to be the most promising monomers.
Figure 1 (new)
Synthesis and characterization of the polymers
Nanogels were synthesized by radical copolymerization of the four functional monomers 2b-5b and acrylamide, with N,N'-ethylenebisacrylamide as the crosslinker, with a total monomer concentration (CM) of 1%, in DMSO and AIBN as initiator as reported in Materials and
Methods. The choice of acrylamide stemmed from the requirement of having polymeric matrices capable to easily dissolve as colloids in water. For the imprinted polymers, the template and the functional monomers, in a 1.2:1 molar ratio, were allowed to form the complex at 25°C for 40 min before polymerization (Pasetto et al. 2005) . Eight nanogels were obtained by this method and their composition and characterisation are presented in Table 1 . With the exception of NIP 0.2, which was poorly soluble, all nanogels showed good solubility and formed stable colloidal solutions in a 10% water : DMSO mixture. This solvent system appeared to be the most suitable and was used throughout for the characterisation. The particle size was evaluated by dynamic light scattering. The data are presented in Table 1and figure S1 which shows a high degree of consistency with particle size by number all comprised between 8 and 15 nm with good consistency. The results suggest that the polymers are mostly found as a fairly homogenous preparation, although the data for size by intensity does suggest the presence of a small fraction of aggregated nanoparticles, leading to the high intensity scattering around 130 nm diameter on average. However, this fraction was estimated to be less than 5% by volume analysis (Long et al. 2011) . The particle size were also confirmed by transmission electronic microscopy, using graphene oxide grid, and the image for the coumarincontaining MIP 1.5 is shown in Figure 2 .
Figure 2 new
The coumarin containing polymers were characterized also by the content of the fluorescent tag incorporated, determined by UV, which showed interestingly some significant differences.
The amount of bound coumarin in NIP 0.5 was found to be 550 pmol/g, over twice the amount found in the imprinted material 1.5, which contained 230 pmol/g of the fluorescent label (Table S2 , Figure S2 ). This would suggests that the formation of the template-monomer complex in the imprinted nanogels significantly impacts the incorporation of the coumarin unit.
NMR experiments carried out with the coumarin monomer indicate that self-association of the monomer occurs at concentrations similar to those used during the nanogel synthesis (11 mM).
This could explain the higher concentration of coumarin tag found in the non-imprinted polymer ( Figure S3 ). The concentration of fluorescent tag in the different polymer preparations was taken into consideration when calculations of imprinting efficiency and rebinding were carried out.
Rebinding and selectivity
Rebinding tests were carried out by HPLC (Table 1 ). The fluorescent MIP 1.5 is the best binder, capturing 35 nmol/mg of the target after several minutes, with good specificity, as indicated by the high value of the imprinting factor obtained. Although Sunitinib is always given in monotherapy without being co-administrated with other drugs, nevertheless the rebinding selectivity of MIP 1.5 was investigated using two common anticancer drugs : SN38 which has a similar shape and size as sunitinib, and paclitaxel, a much large molecule. Under the same experimental conditions the cross reactivity of MIP1.5 with SN38 and paclitaxel was found to be 23% and 3% respectively.
Fluorimetry
The presence of tyrosine, tryptophan and coumarin in the different nanogel preparations allows fluorimetric evaluation of the binding affinity at low drug concentrations. We have studied first the emission spectra of the fluorescent nanogels in their colloidal solutions in both DMSO and then in mixtures of DMSO and water, as these are the conditions in which the nanogels are going to be applied. Characterisation techniques commonly used for bulk polymers or thin films
could not be applied. The emission spectra for tyrosine and trypthopan containing nanogels are reported in the supplementary materials while the emission spectrum of MIP 1.5 is reported in 
where 0 is the lifetime of the fluorophores, which was assumed to be 4.3 ns for coumarin (Boens et al. 2007 ), 3.6 ns for tyrosine and 3.1 ns for tryptophan (Guzow et al. 2004; Szabo 1980) . Even when the lower slope regions of the plots are included, kq app is larger than the limit value for the diffusion controlled quenching (1·10 -10 M -1 s -1 ). Thus, the observed quenching must be the consequence of a static interaction, i.e. the formation of a complex between the emitting polymers and the quencher drug ligand (Lakowicz 2006) . The apparent Stern-Volmer constants can therefore be regarded as apparent association constant for the MIPs-target complexes. The high Stern-Volmer constants measured at drug concentrations lower than 5 M (Table 1) are most likely related to the presence of binding sites with a higher apparent binding affinity.
Interestingly the concentration of such sites is very similar in all imprinted nanogels, suggesting that this is a feature likely to be related to the concentration of functional monomer and crosslinker used in the synthesis. Conversely, lower affinity binding sites on the polymer surface may be associated to the second region of the plots where the slope is similar to that obtained in the titration of the free functional monomers (Table 1 and Figure 3b) . The fluorescence quenching of polymer 1.5, containing the coumarin unit, can be clearly visualised also by naked-eye (Figure 3c and d) .
Detection of sunitinib in plasma MIP 1.5, being the best binder and having excellent fluorescence properties, was chosen as the fluorescent nanogel to be used for the development of a direct assay for sunitinib in plasma samples.
Pre-treatment with a denaturing agent such as methanol or ethanol is generally required for the detection of drugs in plasma, where they are strongly associated to serum albumins. These common denaturing agents, however, cannot be used in this case, as the imprinted polymer releases the target drug when treated with alcohols. Thus, in this assay, DMSO has been used as denaturing agent. The action of DMSO on human plasma is very different from that of alcohol: the latter leads to the denaturation and precipitation of serum albumin, while DMSO leads to unfolding without precipitation (Sterling 2011 , Tjernberg 2006 . DMSO, however, is compatible with the imprinted polymer and we reasoned that serum albumin unfolding would be sufficient to release the albumin-bound drug. The designed assay thus requires simple dilution of the plasma sample in DMSO, addition of the fluorescent MIP and quantification of the fluorescence emission, which compared to a reference sample allows the quantification of the drug present in the plasma.
A calibration curve was initially obtained by titrating 60 g/mL MIP 1.5 with increasing amounts of sunitinib in a 4:1 DMSO : water mixture (Figure 4a) . The titration was repeated in triplicate experiments carried out with different polymer preparations and repeated in different days. The average calibration curve obtained from these titrations (Figure 4a, full circles) shows an excellent precision, with a within-run variability (CV) lower than 9%, and an average within-day variability lower than 5%. From the apparent Stern-Volmer constant for MIP1.5 (Table 1 ) and the observed variability, a value of 400 nM can be obtained as the lower limit of detection of sunitinib, defined as the lowest concentration of sunitinib leading to an emission of polymer fluorescence that can be statistically differentiated from the reference (average emission under 3 from the initial emission). As we have stated in the introduction there are no detection methods for sunitinib other than LC-MS. Clearly LC-MS is more sensitive than our system (which nevertheless is reported here as a non optimized proof of concept that could lead to more sensitive systems when exploited inside an optimized sensing device). However, our aim is to develop a system capable to detect plasma levels of sunitinib over the therapeutic range, and under this point of view, the sensitivity is satisfactory.
a b Figure 4 (new)
Samples spiked with known quantities of sunitinib in both PBS and normal human plasma were treated with four volumes of DMSO to unfold proteins. In plasma, this treatment led to the formation of a small amount of white precipitate likely due to salts (as no absorbance at 280 nm was recorded after redissolving the precipitate in water). After centrifugation, MIP 1.5 was added from a mother solution in DMSO; the emission of the spiked samples was corrected for the emission of a plasma sample not containing sunitinib, and the drug concentration was calculated from the calibration curve obtained in 4:1 DMSO : water (Figure 4) . The real and calculated concentrations of the drug in the spiked samples are reported in Table 2 . Despite the samples were quantified using a calibration curve obtained in a different medium (DMSO :
water), the accuracy was encouraging, and the calculated concentrations correlate well with the theoretical ones in both PBS and plasma solutions. The slope of the linear regression of these data is very close to the theoretical value of 1 for both the plasma samples and the bufferalbumin ones (Figure 4b) . Therefore the robustness of the system upon changing the medium from DMSO : water to DMSO : PBS and DMSO : human plasma, is good.
Conclusions
In conclusion, we have designed and synthesized a set of fluorescent MIPS that bind sunitinib with good sensitivity. We have also developed a novel analytical protocol for the fluorimetric Rebinding measured by HPLC on a 50 M solution containing 1 mg/mL polymer.
3 Apparent Stern-Volmer constant measured at ligand concentrations below and (above) 5M. The Stern-Volmer constants measured for the interactions of 1 with fluorophores 3a, 4a and 5a were 12.7, 12.2 and 18.4 respectively. 4 Apparent quenching constants measured at ligand concentrations below and (above) 5M. The quenching constants measured for the interactions of 1 with fluorophores 3a, 4a and 5a were 3.5, 3.9 and 4.3 respectively. 
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